Fractyl Health, Inc. (GUTS)
NASDAQ:GUTS
Want to see GUTS full AI Analyst Report?
GUTS Stock Chart & Stats
$0.57
-$0.12(-5.94%)
At close: 4:00 PM EST
$0.57
-$0.12(-5.94%)
Day’s Range― - ―
52-Week Range$0.38 - $3.03
Previous Close$1.96
Volume269.01K
Average Volume (3M)2.22M
Market Cap
$133.42M
Enterprise Value$55.85M
Total Cash (Recent Filing)$63.17M
Total Debt (Recent Filing)$60.82M
Price to Earnings (P/E)―
Beta1.28
Next Earnings
Aug 19, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.74
Shares Outstanding158,648,960
10 Day Avg. Volume2,888,784
30 Day Avg. Volume2,220,715
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)17.64
Price to Sales (P/S)0.00
P/FCF Ratio-1.84
Enterprise Value/Market Cap0.42
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.61
Forecast
1Y Price Target
$5.00Price Target Upside777.19% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.45
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Regulatory & Reimbursement MomentumFavorable de novo feedback and Breakthrough Device designation materially improve regulatory path clarity and could shorten time to authorization. Potential CMS RAPID alignment and planned CPT filing create a credible route to faster Medicare coverage and hospital reimbursement, supporting durable commercial access if approvals succeed.
Pivotal Trial Execution & TimelineA large, fully randomized pivotal with high retention reduces trial execution risk and enhances the credibility of efficacy/safety readouts. Clear milestone timing for 6‑month and 12‑month endpoints provides a concrete, near‑term roadmap that underpins regulatory submission planning and longer-term commercial viability if endpoints are met.
Dual Clinical-stage Pipeline (Revita + Rejuva)Advancing Rejuva to first-in-human status while Revita proceeds through a pivotal reduces single‑asset binary risk and creates multiple development and commercial pathways. A device plus gene therapy portfolio enhances long‑term optionality across metabolic disease indications and broadens potential value drivers beyond a single trial outcome.
Bears Say
Limited Cash RunwayWith cash runway only into early 2027 and an explicit plan to avoid raising capital before pivotal readouts, the company faces material financing risk. Any timeline slip, regulatory delay, or higher-than-expected spend could force dilutive financing or operational cutbacks, constraining long‑term execution and commercialization preparations.
Pre-revenue And Persistent Cash BurnSustained, large cash burn with no meaningful revenue means the business lacks internal cash generation to fund development or commercialization. Until Revita/Rejuva translate to commercial revenues, the company will likely need external capital, raising dilution and execution risk and limiting ability to invest in scaling operations.
Elevated Leverage And Historical Balance-sheet StressMeaningful debt relative to a small equity base reduces financial flexibility and increases refinancing risk, particularly for a pre‑revenue biotech. Historical episodes of negative equity highlight prior balance‑sheet vulnerability, which can limit strategic options and worsen outcomes if clinical or market setbacks occur.
Fractyl Health, Inc. News
GUTS FAQ
What was Fractyl Health, Inc.’s price range in the past 12 months?
Fractyl Health, Inc. lowest stock price was $0.38 and its highest was $3.03 in the past 12 months.
What is Fractyl Health, Inc.’s market cap?
Fractyl Health, Inc.’s market cap is $133.42M.
When is Fractyl Health, Inc.’s upcoming earnings report date?
Fractyl Health, Inc.’s upcoming earnings report date is Aug 19, 2026 which is in 80 days.
How were Fractyl Health, Inc.’s earnings last quarter?
Fractyl Health, Inc. released its earnings results on May 12, 2026. The company reported $0.06 earnings per share for the quarter, beating the consensus estimate of -$0.16 by $0.22.
Is Fractyl Health, Inc. overvalued?
According to Wall Street analysts Fractyl Health, Inc.’s price is currently Undervalued.
Does Fractyl Health, Inc. pay dividends?
Fractyl Health, Inc. does not currently pay dividends.
What is Fractyl Health, Inc.’s EPS estimate?
Fractyl Health, Inc.’s EPS estimate is -0.14.
How many shares outstanding does Fractyl Health, Inc. have?
Fractyl Health, Inc. has 158,648,960 shares outstanding.
What happened to Fractyl Health, Inc.’s price movement after its last earnings report?
Fractyl Health, Inc. reported an EPS of $0.06 in its last earnings report, beating expectations of -$0.16. Following the earnings report the stock price went up 29.155%.
Which hedge fund is a major shareholder of Fractyl Health, Inc.?
Currently, no hedge funds are holding shares in GUTS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Fractyl Health, Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.00 (777.19% Upside)
$5.00 (777.19% Upside)
Blogger Sentiment
Bullish
GUTS Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 3.5M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 1.3%
Last 30 Days ▲ 2.6%
Last 30 Days ▲ 2.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-57.57%
12-Months-Change
Fundamentals
Return on Equity
-4573.89%
Trailing 12-Months
Asset Growth
19.68%
Trailing 12-Months
Company Description
Fractyl Health, Inc.
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is based in Lexington, Massachusetts.
GUTS Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasizes strong clinical execution, external validation, regulatory and reimbursement progress, and a clear catalyst timeline — all supportive of the company's strategic thesis. Financially, the company has reduced operating spend and improved adjusted EBITDA, but remains cash-limited with a runway into early 2027 and continues to report negative adjusted profitability. Several regulatory and operational uncertainties remain (RAPID implementation, full de novo approval, U.S. regulatory engagement for Rejuva) and the near-term plan is contingent on multiple upcoming clinical readouts. Overall, clinical and regulatory momentum and cost discipline are material positives, but the constrained cash runway and remaining execution/regulatory risks temper the outlook.View all GUTS earnings summariesGUTS Stock 12 Month Forecast
Average Price Target
$5.00
▲(777.19% Upside)
Technical Analysis
Coherus Biosciences
―
SELLAS Life Sciences Group
―
Protara Therapeutics
―
―
Innate Pharma
―
Ownership Overview
6.53% Insiders
4.29% Mutual Funds
36.26% Other Institutional Investors
49.32% Public Companies and Individual Investors
Options Prices
Currently, No data available
---